Experienced in Osteosarcoma

Marion Gambart

Toulouse, FR 
Experienced in Osteosarcoma
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Marion Gambart practices in Toulouse, France. Gambart is rated as an Experienced expert by MediFind in the treatment of Osteosarcoma. Their top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Osteosarcoma.

Their clinical research consists of co-authoring 39 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Osteosarcoma.

Locations

Toulouse, France
Other Locations
Bordeaux, France
Nantes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Study Phase: Phase 1
Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome
Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drugs: Dexamethasone Acetate, Dexamethasone and Cyclophosphamide, Dexamethasone and Rituximab
Study Phase: Phase 3
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Bevacizumab, Temozolomide, Irinotecan, Topotecan, Dinutuximab Beta, Cyclophosphamide
Study Phase: Phase 2
Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification
Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification
Enrollment Status: Completed
Publish Date: December 01, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
Phase I Study of Fluvastatin-Celebrex Association for Optico-chiasmatic Low Grade Gliomas and High Grade Gliomas Localized Outside the Brainstem, Relapsed or Refactory, in Children or Young Adults
Phase I Study of Fluvastatin-Celebrex Association for Optico-chiasmatic Low Grade Gliomas and High Grade Gliomas Localized Outside the Brainstem, Relapsed or Refactory, in Children or Young Adults
Enrollment Status: Completed
Publish Date: February 10, 2022
Intervention Type: Drug
Study Drugs: Fluvastatine, Celebrex
Study Phase: Phase 1
Feasibility Study of a Treatment Protocol of Pediatric Chemo- and Radiotherapy-induced Oral Mucositis by Low-level Laser Therapy
Feasibility Study of a Treatment Protocol of Pediatric Chemo- and Radiotherapy-induced Oral Mucositis by Low-level Laser Therapy
Enrollment Status: Completed
Publish Date: May 31, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

39 Total Publications

Chemo-Immunotherapy Rescue for High-Risk Neuroblastoma Patients With Progressive Disease Before High-Dose Chemotherapy: Real-World Data From the SACHA-France Study.
Chemo-Immunotherapy Rescue for High-Risk Neuroblastoma Patients With Progressive Disease Before High-Dose Chemotherapy: Real-World Data From the SACHA-France Study.
Journal: Pediatric blood & cancer
Published: May 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gambart's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile